Cognitive enhancing effect of Canagliflozin in aluminum-induced rat model of Alzheimer's-like disease: Cross-talk between Amyloid-Β and BDNF/GSK-3β signaling
European Journal of Pharmacology · 2026
DOI: 10.1016/j.ejphar.2026.178581 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von Raafat A Abdel-Aal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Department, Faculty of Medicine, Assiut University, Assiut, 71526, Egypt. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3 beta, Brain-Derived Neurotrophic Factor, Alzheimer Disease, Amyloid beta-Peptides. Die Arbeit nennt 86 Literaturangaben. Gefördert von: Assiut University, Assiut University Faculty of Medicine.
Themen: Demenz
Abstract (Originalsprache)
The strong relationship between Alzheimer's Disease (AD) and diabetes mellitus (DM) is described by the term "type 3 diabetes". Canagliflozin (CAN), a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is an antidiabetic agent under investigation as a potential new treatment for AD due to its acetylcholinesterase (AChE) inhibitory properties. We aimed to examine the effect of CAN on the efficacy of the anti-acetylcholinesterase, rivastigmine (RIV), against aluminum chloride (AlCl3)-induced AD rat model. The efficacy of CAN, RIV, and CAN plus RIV against abnormal behavioral, biochemical, and histological changes in AlCl3-induced AD in rats was examined. Three weeks of treatment with CAN partially reversed the AlCl3-induced behavioral dysfunction, along with significantly elevated levels of brain-derived neurotrophic factor (BDNF) and decreased levels of AChE, glycogen synthase kinase-3β (GSK3β), amyloid beta (Aβ) deposits, and inducible nitric oxide synthase (iNOS) expression. Histological examination revealed that CAN administration significantly increased RIV's efficacy by protecting neurons in rats' hippocampal tissues from AlCl3-induced damage. Interestingly, the RIV + CAN combination exhibited a more pronounced inhibitory effect on Aβ plaque formation, iNOS activity, and neurodegeneration compared to either RIV or CAN alone. However, this combination did not show any additive benefits for behavior, AChE activity, BDNF, or GSK3β concentrations compared with RIV alone. Our research indicates that CAN has potential benefits for AD, as evidenced by improvements in cognitive abilities, cholinergic activity, and neurogenesis in rats with AD. This is attributed to the upregulation of BDNF/GSK3β signaling, reduced neuroinflammation, and Aβ deposition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacology Department, Faculty of Medicine, Assiut University, Assiut, 71526, Egypt.
- Department of Restorative Dentistry and Basic Medical Sciences, Faculty of Dentistry, University of Petra, Amman, 11196, Jordan; Histology and Cell Biology Department, Faculty of Medicine, Assiut University, Assiut, 715…
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Assiut University, Assiut, 71526, Egypt.
- Pharmacology Department, Faculty of Medicine, Assiut University, Assiut, 71526, Egypt. Electronic address: esraaashry@aun.edu.eg.
Förderung
- Assiut University
- Assiut University Faculty of Medicine
Zitieren
APA
Abdel-Aal, R. A., Meligy, F. Y., Kamel, G., & Ashry, I. E. M. (2026). Cognitive enhancing effect of Canagliflozin in aluminum-induced rat model of Alzheimer's-like disease: Cross-talk between Amyloid-Β and BDNF/GSK-3β signaling. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2026.178581
Vancouver
Abdel-Aal RA, Meligy FY, Kamel G, Ashry IEM. Cognitive enhancing effect of Canagliflozin in aluminum-induced rat model of Alzheimer's-like disease: Cross-talk between Amyloid-Β and BDNF/GSK-3β signaling. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2026.178581
BibTeX
@article{AbdelAal2026,
author = {Abdel-Aal, Raafat A and Meligy, Fatma Y and Kamel, Gehad and Ashry, Israa El-Sayed Mohamed},
title = {Cognitive enhancing effect of Canagliflozin in aluminum-induced rat model of Alzheimer's-like disease: Cross-talk between Amyloid-Β and BDNF/GSK-3β signaling},
journal = {European Journal of Pharmacology},
year = {2026},
doi = {10.1016/j.ejphar.2026.178581}
}
EUVIMED